Global Nirsevimab Market Strategic Research Report

Scope of the Report

The global Nirsevimab market size is predicted to grow from US$ 2,886 million in 2025 to US$ 9,920 million in 2032; it is expected to grow at a CAGR of 19.4% from 2026 to 2032.

In 2025, global Nirsevimab production reached approximately 12 million units.Nirsevimab is a long-acting human immunoglobulin G1 kappa monoclonal antibody targeting the fusion protein of respiratory syncytial virus. It is designed to provide direct and rapid passive immune protection by binding to the prefusion conformation of the RSV F protein, thereby inhibiting viral fusion with host cell membranes and preventing subsequent infection. Approved for use in neonates and infants during their first RSV season, it offers a convenient single-dose administration and an extended half-life to sustain protection throughout the high-risk period, representing an important preventive option for respiratory syncytial virus infection in the pediatric population

Nirsevimab has established a dominant and rapidly expanding position in the global RSV prophylactic market, driven by its transformative clinical profile and unmet medical need. As a long-acting, single-dose monoclonal antibody, it addresses critical limitations of previous therapies by providing immediate, sustained protection for infants through an entire RSV season, fundamentally shifting clinical practice and public health strategies. Its market penetration is fueled by widespread regulatory approvals, formal inclusion in national pediatric immunization guidelines across major markets, and strong real-world evidence demonstrating significant reductions in infant hospitalizations. Despite intensifying competition from emerging RSV antibodies and maternal vaccines, nirsevimab maintains a leading edge through established brand recognition, optimized global supply chains, and expanded geographic reach into high-potential emerging markets. The market landscape continues to evolve with ongoing efforts to balance supply with surging global demand, adapt to evolving clinical recommendations, and navigate pricing and access dynamics across diverse healthcare systems, solidifying its role as a cornerstone in pediatric RSV prevention.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Nirsevimab market?

What factors are driving Nirsevimab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Nirsevimab market opportunities vary by end market size?

How does Nirsevimab break out by Type, by Application?

This report presents a comprehensive overview of the global Nirsevimab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 50 mg (0.5 mL) / syringe
• 100 mg (1.0 mL) / syringe

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Route of Administration

• Intramuscular Injection
• Subcutaneous Injection

Segment by Application

• Prevention Of Respiratory Syncytial Virus Infection
• Reduction Of Severe Lower Respiratory Tract Disease
• Protection Of Infants During Rsv Season
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Nirsevimab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Prevention Of Respiratory Syncytial Virus Infection, Reduction Of Severe Lower Respiratory Tract Disease, Protection Of Infants During Rsv Season evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact